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Summary
The workshop entitled ‘Interventions to Slow Aging in Humans:
Are We Ready?’ was held in Erice, Italy, on October 8–13, 2013,
to bring together leading experts in the biology and genetics of
aging and obtain a consensus related to the discovery and
development of safe interventions to slow aging and increase
healthy lifespan in humans. There was consensus that there is
sufficient evidence that aging interventions will delay and
prevent disease onset for many chronic conditions of adult
and old age. Essential pathways have been identified, and
behavioral, dietary, and pharmacologic approaches have
emerged. Although many gene targets and drugs were dis-
cussed and there was not complete consensus about all
interventions, the participants selected a subset of the most
promising strategies that could be tested in humans for their
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effects on healthspan. These were: (i) dietary interventions
mimicking chronic dietary restriction (periodic fasting mimicking
diets, protein restriction, etc.); (ii) drugs that inhibit the growth
hormone/IGF-I axis; (iii) drugs that inhibit the mTOR–S6K
pathway; or (iv) drugs that activate AMPK or specific sirtuins.
These choices were based in part on consistent evidence for the
pro-longevity effects and ability of these interventions to
prevent or delay multiple age-related diseases and improve
healthspan in simple model organisms and rodents and their
potential to be safe and effective in extending human health-
span. The authors of this manuscript were speakers and
discussants invited to the workshop. The following summary
highlights the major points addressed and the conclusions of
the meeting.
Key words: aging; anti-aging; centenarians; longevity regu-
lation; dietary restriction; lifespan studies; longevity gene.
Introduction
Human aging and age-associated diseases are emerging as among
the greatest challenges and financial burdens faced by developed
and developing countries (Christensen et al., 2009) (http://esa.un.org/
wpp/documentation/pdf/WPP2010_Volume-I_Comprehensive-Tables.pdf).
Although average life expectancy has increased dramatically in the last
100 years, this has not been accompanied by an equivalent increase in
healthy life expectancy, which has been termed healthspan (Hung et al.,
2011). Research related to longevity extension has traditionally been
viewed with skepticism and with concerns that it could lead to an
increase in the size of the elderly population and the prevalence of
diseases associated with aging. However, studies in a wide range of
organisms have demonstrated that major lifespan extension is accom-
panied by reduced or delayed morbidity in most cases (Fontana et al.,
2010). Data from experimental studies in invertebrates and rodents have
consistently shown that both chronic dietary restriction (DR) and
mutations in nutrient and growth signaling pathways can extend
longevity by 30–50%. These interventions can also lower the prevalence
of age-related loss of function and multiple diseases, including tumors,
cardiovascular disease, and neurodegeneration (Fontana et al., 2010).
DR protects against diabetes, cancer, cardiovascular disease, sarcopenia,
and neurodegeneration of certain brain regions in rhesus monkeys and
also extends lifespan (Mattison et al., 2012; Colman et al., 2014). In
humans, long-term DR causes several metabolic and molecular changes
that protect against age-related pathologies, including changes in
markers for type 2 diabetes, hypertension, cardiovascular disease,
cancer, and dementia (Cava & Fontana, 2013). Moreover, chronic DR
ameliorates the expected age-associated alterations in myocardial
stiffness, autonomic function, and skeletal muscle gene expression
changes (Mattison et al., 2012; Cava & Fontana, 2013; Colman et al.,
2014). However, the duration and severity of the DR regimen that is
required for optimal benefits is not feasible for most people and is likely
to be associated with undesirable side effects. Therefore, the focus of
this consensus meeting in Erice was on less drastic dietary interventions
and drugs that target nutrient-response pathways and mimic the effects
of DR, but that are practical, realistic, and safe.
There was a general consensus among this panel of experts on the
following points: (i) aging can be slowed by many interventions; (ii)
slowing aging typically delays or prevents a range of chronic diseases of
old age; (iii) dietary, nutraceutical, and pharmacologic interventions that
modulate relevant intracellular signaling pathways and can be consid-
ered for human intervention have been identified. Additional potential
targets will continue to emerge as research progresses; and (iv) it is now
necessary to cautiously proceed to test these interventions in humans.
Based on a vote taken on the last day of the workshop, the strategies
believed to be most promising by the panel of invited experts and
authors of this manuscript are as follows:
1 Pharmacological inhibition of the GH/IGF-1 axis
2 Protein restriction and Fasting Mimicking Diets
3 Pharmacological inhibition of the TOR -S6K pathway
4 Pharmacological regulation of certain sirtuin proteins and the use
of spermidine and other epigenetic modulators
5 Pharmacological inhibition of inflammation
6 Chronic metformin use
These choices were based in part on: (i) consistent evidence for their
pro-longevity effects in simple model organisms and rodents; (ii)
evidence for their ability to prevent or delay multiple age-related
diseases and conditions; and/or (iii) clinical evidence for their safety in
small mammals and/or nonhuman primates. Below, we present the
salient points related to each of the promising strategies. Other ideas
discussed at the meeting are described elsewhere (Gems, 2014).
Biomarkers to assess the efficacy of interventions
The successful development and implementation of interventions to
promote healthspan will require the use of aging biomarkers. Biomarkers
are defined here as biological characteristics that can be objectively
measured and evaluated as indicators of age-related normal and
pathogenic processes. In practice, such biomarkers should aid in
diagnosing individual aging phenotypes, predicting the progression of
these phenotypes, selecting possible interventions, and evaluating the
effects and outcomes of such interventions. Biomarkers are key for the
development, testing, and implementation of interventions in aging
because of the great difficulty in performing clinical trials. Indeed,
biomarkers of disease are often an aid in clinical trials, For example, to
stratify patients so that only those likely to respond to a particular
therapy receive it. Interventions in aging require biomarkers for all the
same reasons, and also as surrogates for determining the efficacy and
safety of interventions that often require very long time scales. There are
three categories of such biomarkers that should be distinguished:
Biomarkers of critical pro-aging mechanisms
These biomarkers are needed to define the parameters that should be
targeted in interventions. A disease can be defined as a disorder or
abnormality of structure or function. Some have argued that aging
cannot be abnormal because everyone suffers from it, which has led to
the reluctance to accept aging as the equivalent of a disease. This and
the extended period of time that is required to evaluate the effect of
interventions on aging essentially constrain clinical trials to testing the
efficacy of experimental interventions. Hence, biomarkers are needed to
predict the effect of interventions over the long term.
Despite the great progress in our understanding of how lifespan
can be modulated in experimental animals, human aging itself remains
less well understood. Biomarkers need to be defined for those
processes deemed critical for healthy human aging. To develop such
biomarkers, integrated animal–human studies are needed with an
important role for systems biology to understand better the molecular
basis of the critical pro-aging processes targeted for intervention
and the mechanistic rationale of potential interventions. Data on
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epigenetic changes and other ‘omics’ level alterations with potential
significance for critical pro-aging molecular pathways are important to
collect.
Companion biomarkers
For each of the experimental interventions deemed promising enough
for limited human testing, biomarkers need to be developed that are
able to: (i) identify individuals who would benefit from the treatment;
and (ii) help understand and assess the molecular target(s) of the agent
being studied. The high failure rate of new therapies tested in clinical
development accentuates the critical importance of discovering biomar-
ker readouts that can predict efficacy.
Safety biomarkers
The development of 30% of new drug candidates is halted due to
unforeseen toxicity and other adverse side effects in clinical studies. This
is especially relevant for interventions in aging, which cannot be tested
easily in clinical trials and need to be applied over extended periods of
time. Accordingly, greater emphasis must be placed on the development
and use of safety biomarkers in studies of interventions in aging. In this
respect, it is possible to profit from safety biomarkers that have been
developed and accepted over the years, for example, to detect toxicity in
the kidney and liver.
Companion biomarkers and safety biomarkers are not specific to
aging or age-related disease. The challenge to the field is to develop a
consensus panel of biomarkers of aging that can be used in clinical trials,
that is, biomarkers in category 1 above. The following is a list of potential
biomarkers or methods to assess biological age discussed at the
workshop. It does not represent a comprehensive listing of all possible
biomarkers, but a list of potential markers and methods to assess
biological age and the risk of developing age-related diseases suggested
by the participants and discussed at the meeting.
1 Standard frailty measurements (e.g., walking speed at older ages,
hand grip, VO2max)
2 Insulin, insulin resistance, fasting blood glucose + GTT, HbA1c,
adiponectin, DEXA (abdominal adiposity)
3 LDL, HDL, blood pressure, pulse wave velocity, intima media
thickness, left ventricular diastolic function/pressure
4 Inflammatory markers (e.g., CRP, IL-6, TNF-a)
5 Cognitive performance (cognitive tests, fMRIs)
6 Lymphocyte number, lymphoid/myeloid ratio
7 IGF-I, T3
8 Epigenetic profile (e.g., DNA methylation)
9 Renal clearance (age 60–90)
Dietary interventions mimicking calorie restriction
Intermittent and prolonged fasting
Fasting is the most extreme of the DR interventions because it requires
the complete elimination of nutrients. The best-characterized form of
fasting evaluated in both rodent and human studies is intermittent or
alternate-day fasting (IF or ADF), which involves the feeding on every
other day for long periods of time (Trepanowski et al., 2011). Prolonged
fasting (PF), in which water but not food is consumed for two or more
consecutive days, is also becoming a well-investigated intervention,
particularly in rodent models and lower eukaryotes (Longo & Mattson,
2014). The mechanisms of action of fasting are best understood in the
yeast Saccharomyces cerevisiae, in which a switch from glucose-
containing medium to water causes the downregulation of the Tor–
S6K and Ras–adenylate cyclase–PKA pathways, and the consequent
activation of the stress resistance transcription factors Msn2/4 and Gis1,
which regulate many protective and metabolic genes (Wei et al., 2008).
These changes, similar to those observed in starved worms and mice,
promote resistance to both multiple toxins and longevity extension. In
mice, fasting reduces circulating IGF-I and causes downregulation of
PI3K–AKT, Tor–S6K, and adenylate cyclase–PKA signaling, which,
analogously to yeast, results in the activation of multiple transcription
factors including members of the FOXO family of forkhead transcription
factors (Cheng et al., 2014).
Different types of PF or IF have been shown to extend the lifespan of
bacteria, worms, and rodents (Longo & Mattson, 2014). In mouse
models, IF helps to prevent or delay the progression of myocardial
infarction, diabetes, stroke, Alzheimer’s disease, and Parkinson’s disease
(Longo & Mattson, 2014; Mattson, 2014). Similarly, PF protects mice
against the adverse effects of chemotherapy and ischemia/reperfusion-
mediated toxicity as well as cancer progression and promotes stem cell-
dependent regeneration and immune system rejuvenation in old animals
(Mauro et al., 2014, Safdie et al., 2009, Longo & Mattson 2014 Cheng
et al., 2014; Levine et al., 2014). Although the effect of chronic cycles of
PF on healthspan is not known, these studies point to PF, which could be
carried out in humans as infrequently as once a month or less, as a
potent inducer of protective systems and a potential alternative to
chronic CR and IF.
A number of PF and IF clinical studies in humans are yielding very
promising results in support of the possibility that they are sufficiently
safe and effective to be considered for long-term clinical trials focused
on healthspan (Longo & Mattson, 2014). Among the initial but solid
evidence for efficacy is that PF followed by a vegetarian diet reduces
both inflammation and pain in patients with rheumatoid arthritis
(Michalsen et al., 2005). Preliminary studies suggest that PF may also
decrease adverse effects of chemotherapy in humans (Safdie et al.,
2009), a finding now being tested in multiple larger randomized clinical
trials. Part of the protective effects of fasting against aging and disease
may be mediated by the reduction in IGF-1, glucose, and insulin (see
following sections).
The health effects of IF in humans have been investigated more
extensively than those of PF. For example, 3 weeks of alternate-day
fasting reduces body weight, body fat, and plasma insulin concentra-
tions in both men and women (Heilbronn et al., 2005), while a diet of
500–600 calories on 2 of 7 days per week induces loss of abdominal fat,
improves insulin sensitivity, and reduces blood pressure (Harvie et al.,
2010).
PF and IF have few adverse effects, but could be dangerous for
subjects of very low BMI, those who are frail and old, and patients with
diabetes receiving insulin or insulin-like drugs. Thus, the lack of medical
supervision in subjects undergoing IF or PF could result in severe adverse
effects. For example, the insulin-sensitizing effects of PF can cause severe
hypoglycemia and even death in patients with diabetes treated with
insulin. Although major adverse effects caused by IF or PF are rare and
usually reversible, these examples should underscore the potency of
these interventions and their potential to cause remarkably global and
beneficial effects, but also cause detrimental effects if the underlying
mechanism of action are not well understood and they are not properly
tested clinically and implemented. These issues point to the need for the
identification and preclinical/clinical testing of fasting mimicking diets
that match or even surpass the effects of fasting while minimizing the
burden and adverse effects associated with water-only regimens.
Interventions slowing aging, V. D. Longo et al. 499
ª 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Protein restriction or selective amino acid restriction
The benefits attributed to reduced calorie intake could be due, in
part, to the concomitant restriction of proteins or individual essential
amino acids. Restriction of calories in the form of protein contributes
to the benefits of DR on animal longevity (Gallinetti et al., 2013;
Mirzaei et al., 2014). Restriction of individual essential amino acids,
including methionine and tryptophan, can also extend longevity
(Spindler, 2009). Notably it remains unclear whether the underlying
mechanisms responsible for increased longevity overlap with those of
other DR regimens. It is also not known whether there is some
specificity to the effects of restriction of different essential amino
acids.
Amino acid levels are sensed by at least two evolutionarily conserved
mechanisms: one involving GCN2 (general control nonderepressible 2)
and the other involving mTOR. In mammals, mTOR is activated by amino
acids, particularly leucine, while GCN2 is activated by the absence of
many individual amino acids. Mechanisms of protection downstream of
GCN2 activation and mTOR repression subsequent to protein/amino acid
starvation remain largely unknown. However, the transcription factor
ATF4 is stabilized upon GCN2 activation and could be a key mediator in
a variety of extended longevity models, including hypopituitary dwarf
models and methionine restriction (Li et al., 2014).
The major factor controlling the longevity benefits of protein
restriction in multiple species is the ratio of dietary protein to other
macronutrient calorie sources (carbohydrates, fats), which is likely to
affect aging in part through the regulation of mTORC1 signaling
(Solon-Biet et al., 2014). Longevity extension by methionine restriction
in yeast requires GCN2 (Wu et al., 2013), but other mechanisms
including autophagy (Ruckenstuhl et al., 2014) and retrograde signal-
ing from mitochondria (Johnson & Johnson, 2014) are implicated. In
yeast, deficiencies in serine, threonine and valine, extend longevity by a
mechanism involving the down-regulation of orthologs of mammalian
PDK and Tor-S6K proteins (Mirisola, et al., 2014). In flies, reduced
dietary methionine also extends longevity although the mechanism
responsible for this effect is poorly understood (Lee et al., 2014). It has
been shown that GH signaling is necessary to discriminate levels of
dietary methionine in mice (Brown-Borg et al. 2014). In rodents,
protein/amino acid restriction also offers health benefits in models of
acute stress and chronic disease. Eliminating tryptophan from the diet
for 1 week increases the resistance to the acute stress of ischemia/
reperfusion injury in liver and kidney and this depends on GCN2 (Peng
et al., 2012). However, GCN2 is no longer necessary for this beneficial
effect when animals are also deprived of total protein. Instead,
mTORC1 downregulation is key to stress resistance in this case. This
effect could be mediated in part through the negative action of
mTORC1 on insulin sensitivity, such that its downregulation allows for
increased pro-survival signaling after reperfusion (Harputlugil et al.,
2014).
Benefits of short-term protein deprivation also include protection
from intimal hyperplasia (Mauro et al., 2014). Similarly, cycles of protein
deprivation lasting 1 week, followed by a week of ad libitum access to a
complete diet, protect against Tau phosphorylation in a mouse model of
Alzheimer’s disease (Parrella et al., 2013). Finally, protein restriction has
beneficial effects on metabolism, activating a fasting-like response that
requires both GCN2 and PPAR-alpha (peroxisome proliferator-activated
receptor-alpha), and that causes an increase in the fasting hormone
FGF21 (Laeger et al., 2014).
To date, very few studies have been performed in humans on the
potential beneficial effects of protein and/or amino acid restriction on
aging processes or age-associated chronic diseases (Cavuoto & Fenech,
2012; Mirzaei et al., 2014). In agreement with mouse studies (Solon-Biet
et al., 2014), the lowest protein intake was associated with reduced risk
for cancer incidence and overall mortality, but only in the 65 and
younger group of individuals (Levine et al., 2014). Because of the
inefficient utilization of dietary protein associated with differences in
protein quality (i.e., essential amino acid composition and digestibility),
the minimum recommended intake, which has been set at 0.66 g/kg/
day for men and women 18 years or older, is likely to be higher in the
elderly compared to that in younger adults (Levine et al., 2014).
Pharmacological interventions mimicking calorie
restriction
Inhibitors of the TOR pathway
The mTOR pathway has now been linked to lifespan and healthspan in
several major model organisms and species. For instance, reduced mTOR
signaling through genetic or pharmacological interventions leads to
lifespan extension in yeast, worms, flies, and mice (Johnson et al., 2013),
and studies are currently being conducted in primates and humans.
Thus, mTOR signaling is a major candidate for targeted interventions.
The mTOR kinase exists in two complexes: mTORC1 and mTORC2
(Laplante & Sabatini, 2012). Most studies indicate that reduced mTORC1
signaling confers longevity benefits (Johnson et al., 2013). However,
individually reducing either mTORC1 or mTORC2 signaling extends
worm lifespan (Vellai et al., 2003; Soukas et al., 2009). In addition to
being responsive to insulin/IGF signaling, mTORC1 is activated by amino
acids through the RAG GTPase complex and suppressed by stress signals
or energy deficiency (Kim et al., 2013). In short, mTORC1 activation
leads to protein translation and cell growth, whereas its inhibition blocks
growth and induces stress response pathways such as autophagy
(Laplante & Sabatini, 2012).
Many of the interventions that extend lifespan in model organisms
have the effect of reducing mTORC1 signaling (Johnson et al., 2013;
Kennedy & Pennypacker, 2014). These include protein and calorie/
dietary restriction and reduced insulin/IGF signaling, as well as activation
of AMP kinase and possibly of sirtuins, raising the question of whether
the benefits of these interventions are, at least in part, dependent on
their effects on mTORC1. Another fundamental question involves the
downstream pathways of mTORC1 that mediate the longevity effects.
Two major substrates of mTORC1, S6 kinase and 4E-BP1, are both linked
to longevity. Loss of S6 kinase promotes longevity in yeast, flies, worms,
and mice (Johnson et al., 2013), and increased 4E-BP1 activity promotes
longevity at least in flies. In C. elegans, the DAF-16/FOXO transcription
factor is required for lifespan extension in S6 kinase-defective mutants
(Seo et al., 2013), as is autophagy (Hansen et al., 2008). Interestingly,
DAF-16/FOXO and autophagy are both required for impaired insulin/IGF-
1 signaling to extend lifespan in worms (Kenyon et al., 1993; Melendez
et al., 2003), further linking these two perturbations.
An appealing aspect of considering mTOR as a target for anti-aging
interventions is the availability of rapamycin, a pharmacological agent
that is a specific inhibitor of mTOR, and that has been shown to extend
lifespan in mice, up to 30% in females at high doses and to a lesser
extent in males (Harrison et al., 2009; Miller et al., 2014). Rapamycin is
not an active site inhibitor, but rather creates a trimolecular complex
between the mTOR kinase and an FKBP protein, most notably FKBP12
(Brown et al., 1994; Sabatini et al., 1994; Marz et al., 2013). This
action disrupts the mTORC1 complex leading to acute inhibition and
prevents newly synthesized mTOR from entering either mTORC1 or
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mTORC2, leading to chronic inhibition of both complexes (Sarbassov
et al., 2006).
Rapamycin has been studied for decades, tested in hundreds of
clinical trials, and approved for use in several clinical conditions, including
kidney cancers (Lamming et al., 2013; Kennedy & Pennypacker, 2014).
However, rapamycin has important side effects, which limits its
consideration as an anti-aging therapy. The adverse effects of rapamycin
include metabolic dysregulation (e.g., hyperglycemia, hyperinsulinemia,
and insulin resistance), proliferative defects in hematopoietic lineages,
and others (Soefje et al., 2011). The metabolic side effects of rapamycin
have been attributed to inhibition of mTORC2 (Lamming et al., 2012),
suggesting that it may be possible to enhance efficacy-to-adverse effect
ratios by specifically inhibiting mTORC1. Safety studies using rapamycin
have been not been conducted in healthy people, so it is not clear
whether rapamycin is harmful in healthy adults. Currently, several trials
testing rapamycin are ongoing in healthy older populations, which will
help evaluate the importance of mTOR in human aging and determine
whether mTOR should be considered a target for interventions to extend
healthspan.
In summary, ongoing studies to address the role of mTOR in aging
and to determine whether it is a valuable target for interventions to
extend healthspan are extensive and will likely shed light on these
important questions in the near future.
Inhibitors of glycolysis
Another area that is being actively explored as a strategy of mimicking
DR is the inhibition of enzymes within the glycolytic pathway (Minor
et al., 2009). It has been suggested that this strategy could provide a
more effective upstream targeting to produce DR-like effects rather than
targeting single downstream pathways. The rationale is that a greater
cascade of responses could be activated, although this could also lead to
a broader range of adverse effects (Minor et al., 2009). The first
candidate drug in this category, 2-deoxy-D-glucose (2DG), which inhibits
phosphoglucose isomerase, produced a remarkable phenotype similar to
DR when fed to rats (Minor et al., 2009); however, other long-term
studies reported that the concentrations necessary to elicit DR-like
physiological responses also had cardiotoxic effects (Ganapathy-Kan-
niappan & Geschwind, 2013).
Recent preliminary studies have reported promising results with a
nutraceutical product made from unripened avocados containing a
seven-carbon sugar, mannoheptulose, which inhibits hexokinase (Minor
et al., 2009). Studies in mice and dogs showed that the avocado extract
improved insulin sensitivity as well as increased median lifespan in
nematodes and mice. Additionally, there is currently great interest in
applying glycolytic inhibitors in the treatment of cancer, as many tumor
cells switch their metabolism to glucose as the major energy source
(Ingram & Roth, 2010).
Mice with dysfunctional telomeres and senescent cells in culture
display increases in energy demand and defects in mitochondrial
biogenesis (Passos et al., 2010). In this context, supplementation with
glucose improves tissue and body weight maintenance, increasing their
lifespan (Missios et al., 2014). These results may appear counterintuitive
as they suggest that an increase in dietary glucose can help maintain
energy and tissue homeostasis at advanced age. Of note, however,
malnutrition is present in more than 30% of geriatric patients.
Furthermore, this requirement for additional glucose at older ages is
analogous to that described above for protein, underscoring the need
for a better understanding of optimal age-specific dietary composition
and intake.
Inhibitors of the GH/IGF-1 axis
Although the lack of global IGF-1 signaling is lethal, data from studies
conducted in animal models have shown that a reduction in IGF-1 levels
or IGF-1 action can extend lifespan. Additionally, human IGF-1 receptor
gene polymorphisms are associated with exceptional longevity (Suh
et al., 2008), and recently, Barzilai and colleagues have shown that low
plasma IGF-1 concentrations predict survival in long-lived people
(Milman et al., 2014), specifically in women with a history of cancer.
In animals, dwarf, long-lived mice lacking the growth hormone receptor
(GHR-/-) have reduced levels of IGF-1, are insulin sensitive despite obesity,
and have decreased risk for cancer and diabetes (Zhou et al., 1997;
Shevah & Laron, 2007; Ikeno et al., 2009). Importantly, similar results
have been reported in growth hormone receptor-deficient Laron
syndrome (LS) patients. In this regard, no formal aging studies have
been performed on patients with LS; however, they are protected from
diabetes and fatal neoplasms. (Guevara-Aguirre et al., 2011; Steuerman
et al., 2011). Thus, pharmaceutical interventions that directly lower IGF-
1 levels in adults could improve health and prolong lifespan.
Pharmacological targets for lowering IGF-1 action include those that
act directly or indirectly on cells/tissues that produce or respond to GH
and/or IGF-1. In this regard, human or humanized monoclonal antibodies
and drugs directed against the IGF-1R have been used in clinical trials to
treat several types of cancer (Warshamana-Greene et al., 2005; Carboni
et al., 2009); however, none have been approved for clinical use. We are
unaware of the development of any antibody against GH or IGF-1, but
several classes of compounds that inhibit the GH/IGF-1 axis have been
approved for use in patients with acromegaly. Recently, a consensus
document has been developed for the use of this therapeutics (Giustina
et al., 2014). One of these drug classes, somatostatin analogues, lower
serum GH levels by suppressing GH secretion by pituitary somatotrophs,
thereby ultimately decreasing serum IGF-1 levels. Unfortunately, these
compounds also suppress secretion of other endocrine hormones,
including insulin. Furthermore, only 20-50% of patients with acromegaly
respond to these drugs, and significant adverse events have been
documented including gallstones, diarrhea, and anorexia. Thus, the use
of somatostatin analogues to increase longevity or healthspan appears to
be unwarranted at this time.
The second approved drug for treating acromegaly is the GH receptor
antagonist pegvisomant (Trainer et al., 2000; van der Lely et al., 2001;
Kopchick et al., 2002; van der Lely & Kopchick, 2006). Pegvisomant is
unique in that it does not inhibit GH secretion, but rather inhibits GH
action by binding to and blocking the GHR (Kopchick et al., 2002).
Notably, a dose-dependent decrease of IGF-1 levels is seen in up to 90%
of pegvisomant-treated patients (Trainer et al., 2000; van der Lely et al.,
2001; Kopchick et al., 2002; van der Lely & Kopchick, 2006). Addition-
ally, pegvisomant is an insulin sensitizer that blocks the diabetogenic
action of GH and thus produces beneficial effects on glucose metab-
olism. Pegvisomant, therefore, could have positive effects on both
longevity and healthy aging by lowering serum IGF-1 and increasing
insulin sensitivity. Regarding adverse effects, van der Lely et al. (2012)
reported that Long-term data on the efficacy and safety profile of
pegvisomant are reassuring and few long-term serious adverse events
have been reported but ongoing vigilance is required to monitor liver
function and tumor size. Thus, pegvisomant is an approved drug that
should be tested for its effects on longevity and healthy aging. Future
therapeutics targeted at inhibiting the GH/IGF-1 axis could include small
inhibitory RNAs directed against the GHR or IGF-1 receptor mRNAs,
monoclonal antibodies directed against GH or IGF-1, or novel GHR or
IGF-1R tyrosine kinase inhibitors.
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Another way to reduce global IGF-1 action may be to inhibit IGF-1
availability. For example, loss of PAPP-A, a protease that cleaves and
inactivates the IGF-1 sequestering protein IGFBP-4, reduces IGF-1-
induced signaling without affecting overall serum IGF-1 levels and not
only extends mouse lifespan, but has many other beneficial effects on
healthspan and age-related diseases (Conover, 2012).
In summary, reducing the activity of the GH/IGF-I somatotrophic axis
is perhaps the most validated and consistent genetic intervention to
extend mouse lifespan and healthspan. In addition GHR/IGF-I deficiency
is also among the few phenotypes that is well characterized in humans
(patients with Laron syndrome) with very few side effects in adults, even
considering the extreme level of GH receptor deficiency and the resulting
>80% reduction in circulating IGF-I. Notably, a pharmaceutical inter-
vention targeting this pathway may or may not be designed to achieve
such a low level of hepatic IGF-I secretion.
Activators of the sirtuin pathways
The deacetylases known as sirtuins (SIRT1 to 7) promote longevity in
diverse species and could mediate many of the beneficial effects of DR
(Satoh et al., 2013). Given their apparent role in mediating health
benefits, sirtuins have attracted considerable interest as a drug target.
The first potent sirtuin-activating compounds (STACs) to be identified
included several classes of plant-derived metabolites, such as flavones,
stilbenes, chalcones, and anthocyanidins. These phytochemicals directly
activate SIRT1 in vitro through an allosteric mechanism that lowers
substrate Km (Howitz et al., 2003). Resveratrol (3,5,4
0-trihydroxystilbene)
is still the most potent of these natural activators identified to date. The
discovery of natural STACs prompted the production of synthetic SIRT1
activators that are considerably more potent, soluble, and bioavailable
(Hubbard & Sinclair, 2014). In many studies, resveratrol and synthetic
STACs have been shown to induce physiological and gene expression
changes that are similar to DR, and improve function and extend the
lifespan of numerous organisms including S. cerevisiae, C. elegans,
D. melanogaster, N. furzeri (a short-lived fish), and A. mellifera (Hub-
bard & Sinclair, 2014).
An alternative approach to activating sirtuins, which raises the activity
of the entire family of enzymes, is to exploit their common requirement
for NAD+. NAD+ levels can be increased by providing NAD precursors
(NMN or NR), by activating NAD biosynthetic enzymes (Wang et al.,
2014a), or by inhibiting the NAD hydrolase CD38 (Yoshino et al., 2011;
Canto et al., 2012; Escande et al., 2012; Gomes et al., 2014).
In mice, resveratrol extends lifespan when given to animals on a high-
fat diet (Pearson et al., 2008) and in combination with standard chow
when fed every other day (Baur et al., 2006; Pearson et al., 2008), but
not when provided daily with standard chow (Pearson et al., 2008;
Strong et al., 2013). Synthetic activators SRT1720 and SRT2104 also
extend the lifespan of mice fed either a high-calorie or a low-calorie diet,
and both protect mice against age-related changes in multiple tissues
including muscle loss (Minor et al., 2011). In preclinical models, STACs
have also shown considerable promise in treating diseases and compli-
cations associated with aging including cancer, type 2 diabetes,
inflammation, cardiovascular disease, stroke, and hepatic steatosis
(Hubbard & Sinclair, 2014).
Considerable progress has been made in the use of STACs to treat
inflammatory and autoimmune disorders (Hubbard & Sinclair, 2014). For
example, SRT1720 has beneficial effects in mouse models of chronic
obstructive disease and asthma. In rhesus monkeys fed a high-fat, high-
sugar diet, resveratrol exerts anti-inflammatory effects in visceral white
adipose tissue (Jimenez-Gomez et al., 2013). STACs could also be
beneficial in neurodegeneration (Zhao et al., 2013) based on mouse
models of Alzheimer’s or Parkinson’s disease and multiple sclerosis (Graff
et al., 2013; Hubbard & Sinclair, 2014). STACs prevent and reverse the
effects of obesity and age-related metabolic decline. In mice fed a high-
calorie diet, resveratrol and STACs protect against obesity, increase
insulin sensitivity, increase mitochondrial function, and prevent liver
steatosis (Baur & Sinclair, 2006; Baur et al., 2006). These effects are also
seen in nonhuman primates fed a high-fat, high-sugar diet (Fiori et al.,
2013; Jimenez-Gomez et al., 2013). Data from studies conducted in
mouse models of obesity and aging have demonstrated that increasing
NAD+ levels protects mice from metabolic decline and aging (Yoshino
et al., 2011; Canto et al., 2012; Escande et al., 2012) and reverses
mitochondrial decline, inflammation, and markers of muscle wasting
(Gomes et al., 2014).
A considerable amount of data has accumulated on treating humans
with STACs (Hubbard & Sinclair, 2014). Resveratrol has had mixed
efficacy, in that its insulin-sensitizing effects (Ghanim et al., 2011;
Smoliga et al., 2011) and DR-like phenotypes have been observed in
elderly and obese humans (Timmers et al., 2011), but not in nonobese
subjects with normal glucose tolerance (Yoshino et al., 2012). This
suggests that STACs may restore homeostasis preferentially in metabol-
ically compromised individuals. A meta-analysis of six unique datasets,
including a total of 196 patients with type II diabetes (104 resveratrol, 92
control/placebo) showed statistically significant (P < 0.05) positive
effects of resveratrol supplementation compared to placebo/controls
for systolic blood pressure, hemoglobin A1c, and creatinine, but not for
fasting glucose, homeostatic model assessment of insulin resistance,
diastolic blood pressure, insulin, triglycerides, LDL, or HDL cholesterol
(Hausenblas et al., 2014). Synthetic STACs have been tested in humans
and are currently in clinical development (Venkatasubramanian et al.,
2013; Hubbard & Sinclair, 2014). Human clinical studies with NAD+
precursors are expected in the next couple of years.
In summary, sirtuins and sirtuin activators have been implicated in
longevity extension as well as in the prevention and treatment of a wide
range of diseases in rodent models. However, there was not full
consensus among meeting participants about the ability of sirtuin
activators to slow aging, given long-running controversies in this area
(Ledford, 2010; Couzin-Frankel, 2011).
Activators of the AMPK pathway
AMP-activated protein kinase (AMPK) is a conserved, energy-sensing
serine/threonine kinase that is activated when cellular energy levels are
low, resulting in increasing levels of AMP (Ruderman & Prentki, 2004).
AMPK activation generates insulin-sensitizing effects resulting in
increased glucose uptake in skeletal muscles, and decreased hepatic
glucose production and enhanced fatty acid oxidation in several tissues
(Ruderman & Prentki, 2004; Ruderman et al., 2013). Activators have
been developed, such as 5-aminoimidazole-4-carboxamide riboside
(AICAR), and some FDA-approved drugs such as biguanides, thiazolid-
inediones, glucagon-like peptide-1 receptor agonists, salicylates, and
resveratrol have AMPK-activating properties (Coughlan et al., 2014).
The biguanide, metformin, which is a first line therapy for type 2
diabetes mellitus (T2DM) activates AMPK in the liver (Rena et al., 2013).
Evidence from animal models and in vitro studies suggests that
metformin changes metabolic and cellular processes (Cabreiro et al.,
2013) associated with the development of age-related conditions
(Ruderman & Prentki, 2004). Notably, treatment of rats (Anisimov,
2010) mice (Martin-Montalvo et al., 2013) and nematodes (Cabreiro
et al., 2013) with metformin extends lifespan. Exercise also stimulates
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AMPK and causes stimulation of glucose uptake and mitochondrial
biogenesis during and after exercise. AICAR administration closely
mimics these effects (Hayashi et al., 1998; Song et al., 2002).
Numerous studies are now focused on whether anti-aging effects
of metformin can be demonstrated in patients with T2DM. Notably, in
the United Kingdom Prospective Diabetes Study (UKPDS), metformin
use, compared with other antidiabetic drugs, decreased the risk of
cardiovascular disease (Group, 1998), cancer incidence and overall
mortality (Wu et al., 2014), and possibly cognitive decline (Ng et al.,
2014). Safety has been established and the pro-longevity effects noted
would argue for testing the use of metformin in humans. However, to
consider metformin for clinical trials testing its potential anti-aging
effect, it will be important to closely examine the known effects of
long-term use on a wide range of subjects and particularly those who
are relatively healthy, but also those with specific conditions for whom
chronic metformin use may have been shown to be detrimental. For
example, recent evidence indicates that metformin also promotes
inhibition of mitochondrial glycerophosphate dehydrogenase and
gluconeogenesis, suggesting that only a partial understanding of the
mechanisms of action of this powerful drug is known, and that further
studies are necessary to determine whether it should be considered for
treating generally healthy or relatively healthy populations (Madiraju
et al., 2014). In fact, gluconeogenesis is required during fasting but
also plays an important role in people consuming ketogenic diets,
which may potentially make metformin dangerous for a subset of the
population on diets that are relatively common and depend on
gluconeogenesis.
Inhibitors of inflammatory pathways
Chronic, low-grade inflammation is recognized as a major characteristic
of aging. This phenomenon is so pervasive that the term inflammaging
(Franceschi et al., 2000; Franceschi & Campisi, 2014) has been coined to
emphasize that many major age-related disabilities, including cancers,
susceptibility to infections, and dementia have immunopathogenic
components (Franceschi & Campisi, 2014). Thus, as inflammation is
associated with many age-related conditions, genes and pathways that
regulate inflammation are candidate targets to combat them (Franceschi
& Campisi, 2014). Inflammaging appears to be much more complex than
we previously thought, and a variety of tissues and organs participate in
producing inflammatory stimuli (Franceschi et al., 2007; Cevenini et al.,
2012). The list is extensive and includes the immune system, but also
adipose tissue, skeletal muscle, liver, and the gut. The gut is of unique
importance, because it is the body’s largest immune organ and contains
trillions of bacteria that can release inflammatory stimuli into the portal
and systemic circulation (Biagi et al., 2010).
Despite its importance, mechanistic details for the most important
stimuli that trigger inflammaging remain unknown, and much additional
investigation is needed. Stimuli triggering inflammation can be exoge-
nous (e.g., persistent cytomegalovirus infection) (Sansoni et al., 2014),
but most are probably endogenously produced, possibly coming from
the ‘self-debris’ resulting from the continuous turnover of cells and
tissues (Franceschi & Campisi, 2014). For example, circulating mitochon-
drial DNA (mtDNA) is recognized by immune sensors as a foreign nucleic
acid, is a powerful inflammatory stimulus, and increases with age (Pinti
et al., 2014). Pro-inflammatory galactosylated N-glycans, which also
represent one of the most powerful biomarkers of biological age in
humans (Dall’Olio et al., 2012), and pro-inflammatory circulating micr-
oRNA (‘inflammaMIR’) (Olivieri et al., 2013) also increase in circulation
with age and could contribute to inflammaging.
The most important drivers of age-dependent inflammation probably
lie at the cellular and molecular levels. Cellular senescence is associated
with a pro-inflammatory senescence-associated secretory phenotype
(SASP), which is triggered by damaging agents (radiation, viruses) and
possibly by continuous exposure to cellular debris (Coppe et al., 2010).
Cellular senescence can also spread to neighboring cells (Jurk et al.,
2014). Second, DNA and telomere damage caused by reactive oxygen
species and other agents can trigger an inflammatory DNA damage
response (Vitale et al., 2013). Third, activation of inflammasomes and
the NF-kB pathway can be elicited by ROS and cellular debris (Youm
et al., 2013). These mechanisms provide many targets for therapies to
decrease inflammaging either locally or systemically. Possible strategies
to target them include elimination of senescent cells (e.g., by NK cell
activation)(Tchkonia et al., 2013), de-activation of inflammasomes
(Youm et al., 2013), diets enriched with omega3 fatty acids (the
‘Mediterranean diet’)(Berendsen et al., 2013), and other nutritional
strategies, such as DR discussed above.
In mouse studies, anti-inflammatory drugs showed a potential for
extending lifespan, although their effects were relatively small (Strong
et al., 2008); for example, nordihydroguaiaretic acid (NDGA) and aspirin
increased survival but did not extend maximum lifespan. Other anti-
inflammatory drugs were not effective in lifespan extension, underlining
the need for additional and larger studies to determine the potential of
NSAID and other anti-inflammatory drugs in extending human health-
span.
Modulators of epigenetic pathways
The term epigenetics denotes heritable phenotypic alterations caused by
postreplicative modifications of chromatin, rather than classical muta-
tion-based genetic changes. Such covalent and noncovalent modifica-
tions of DNA and proteins (e.g., histones) alter the state of chromatin
conformation and elicit corresponding changes in transcriptional activity
(Jaenisch & Bird, 2003; Goldberg et al., 2007; Baker et al., 2008).
Epigenetic effects can be elicited by three distinct principal means: (i)
DNA methylation; (ii) post-translational histone modifications; and (iii)
noncoding RNA interference (Goldberg et al., 2007; Baker et al., 2008).
Twin studies suggest that genetics at birth determines only 25% of
lifespan; therefore, it is proposed that epigenetic factors also contribute
to aging. Such epigenetic factors are likely influenced by lifestyle, diet,
and exogenous stress, raising the possibility that strategies can be
developed to ameliorate age-associated cellular dysfunction (Imai et al.,
2000; Longo, 2009).
Although manipulation of enzymes (sirtuins, histone acetyltransfe-
rases, histone deacetylases) that regulate the (de)acetylation status of
chromatin (and other targets) can prolong lifespan in yeast, flies, and
worms, the role of histone modifications in lifespan regulation is poorly
understood. A fly model has recently been introduced in which the
impact of such histone mutations on aging and lifespan can be evaluated
(Pengelly et al., 2013).
A naturally occurring polyamine, spermidine, directly inhibits histone
acetyltransferases (HATs), thereby maintaining histone H3 in a hypo-
acetylated state (Eisenberg et al., 2009). Functionally, this results in
higher resistance to heat and oxidative stress as well as markedly
reduced rates of cell necrosis during aging in human and yeast cells.
Strikingly, this mechanism extends chronological lifespan across species,
including flies, nematodes, and human cells. These data support the
existing body of knowledge regarding histone acetylation in lifespan
maintenance, including the finding that deletion of sas2, encoding a
histone acetyltransferase, extends the replicative lifespan in yeast (Dang
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et al., 2009). Sas2 antagonizes Sir2, a prominent histone deacetylase
involved in aging, and its deletion stabilizes Sir2 levels in aging cells,
thereby allowing a low basal level of acetylation on specific histone
residues associated with longevity regulation (Raisner & Madhani, 2008).
Finally, a simple way to change age-related histone acetylation consists
of dietary strategies that deplete cellular acetyl CoA, the sole donor for
acetylation reactions. Indeed, depletion of acetyl CoA has been recently
shown to be sufficient for autophagy induction and lifespan extension,
although it is not known whether these effects are dependent on
epigenetic changes (Eisenberg et al., 2014; Marino et al., 2014).
In humans, only nontoxic natural substances such as spermidine or
resveratrol, which lead to deacetylation of chromatin, should be
considered for clinical testing (Morselli et al., 2011). As a caveat,
mechanistic understanding of this strategy is highly challenging as the
drugs could have many off-target effects and even at the epigenetic
level, the integrated response of multiple histone sites might be needed
to mediate anti-aging effects. However, data from mice and humans
indicate that spermidine has the potential to be safe for testing its
epigenetic-dependent and independent effects on human healthspan. In
one human study, a polyamine-rich traditional Japanese food (fermented
soybeans) showed significant enhancement of polyamine concentration
in the blood of the participants without obvious adverse effects (Soda
et al., 2009).
Other promising potential drugs and drug targets
b2-adrenergic receptor (b2AR) signaling
Chronic administration of b2AR agonists increases mortality and
morbidity (Ho et al., 2010). Conversely, b2AR antagonists (b-blockers)
decrease mortality after myocardial infarction and improve the health of
individuals with heart failure (Bristow, 2000; Ellison & Gandhi, 2005).
Oral administration of the b-blockers, metoprolol and nebivolol, begin-
ning at 12 months of age, increased the mean and median lifespan of
isocalorically fed male C3B6F1 mice by 10 and 6.4%, respectively
(Spindler et al., 2013). Neither drug affected body weight or food
intake, eliminating DR or altered energy expenditure as explanations for
these effects. The drugs also extended Drosophila lifespan without
affecting food intake. The effects of long-term administration of b-
blockers on human healthspan need to be investigated further in mice
and humans before they can be considered for anti-aging interventions
in healthy individuals.
Meso-nordihydroguaiaretic acid (NDGA)
NDGA is a lignin present at high concentrations in creosote bushes
(V.E.Tyler, 1994). Oral administration of NDGA extends Drosophila and
mouse lifespan (Spindler et al., 2014). Studies in vitro show that NDGA
inhibits intercellular inflammatory signaling, tumor cell proliferation,
insulin-like growth factor-1 (IGFIR) and HER2 receptor activation, and
oxidative phosphorylation (Pardini et al., 1970; Lu et al., 2010). NDGA
reduces weight in a dose-dependent manner without change in food
consumption, suggesting it either decreases absorption or increases
caloric utilization (Spindler et al., 2014) NDGA was not overtly toxic in
mice, but was associated with increased liver, lung, and thymus tumors,
as well as peritoneal hemorrhage (Spindler et al., 2014). Less toxic
derivatives of NDGA should be explored as anti-aging therapeutics in
preclinical trials (Meyers et al., 2009; Castro-Gamero et al., 2013),
although the associations with toxicities make it an unlikely candidate for
human healthspan interventions.
Statins and angiotensin-converting enzyme (ACE) inhibitors
Statins (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors) reduce age-related heart arrhythmias (Ludman et al., 2009;
Spindler et al., 2012) and mortality from multiple types of cancer
(Zeichner et al., 2012; Nielsen et al., 2013). The health benefits of
statins stem from reduced protein isoprenylation (Spindler et al.,
2012) and reduced cholesterol biosynthesis (Ludman et al., 2009).
Statins increase the lifespan and healthspan of Drosophila by
decreasing protein isoprenylation (Spindler et al., 2012). ACE inhibitors
are antihypertensives (Crowley et al., 2012) that reduce AT1R activity,
thereby reducing mortality and morbidity secondary to myocardial
infarction (Corvol et al., 2004; Gradman, 2009; Hoogwerf, 2010;
Crowley et al., 2012), and mitigating adverse cardiac events in
patients with congestive heart failure (Corvol et al., 2004; Gradman,
2009; Hoogwerf, 2010; Crowley et al., 2012). Combined oral
administration of statins and ACE inhibitors extends mouse lifespan
by approximately 9% without affecting serum cholesterol or food
intake. However, monotherapy with either drug is not effective.
Statins and ACE inhibitors are generally well tolerated, and together,
they could increase the lifespan of normotensive, normocholestero-
lemic individuals. Further studies and the understanding of their
mechanisms of action and potential effects on aging are necessary
before they can be considered anti-aging drugs. Considering the very
wide use of statins in many countries, we should be able to begin to
investigate its broader healthspan effects on the relatively healthy
populations being treated for mildly elevated cholesterol.
Hexosamine pathway and glycobiology
The hexosamine pathway produces the metabolite uridinediphosphate
N-acetylglucosamine (UDP-GlcNAC), which is the precursor for N-linked
glycosylation in the endoplasmic reticulum, and O-linked glycosylation
in cytosol and other compartments. Activation of this pathway through
gain-of-function mutations in the enzyme GFAT-1 (glutamine fructose
6-phosphate amino transferase) results in excess UDP-GlcNAC, and
extension of C. elegans lifespan (Denzel et al., 2014). Activation of the
hexosamine pathway or upregulation of GlcNAC enhances several
aspects of protein quality control, including proteasome activity,
autophagy, and ER-associated degradation pathways, which collectively
lead to alleviation of phenotypes in models of proteotoxic disease. In
mice, ischemia/reperfusion of the heart triggers the ER stress response,
with upregulation of GFAT as one of the consequences. GFAT
upregulation or GlcNAC treatment was reported to protect against
ischemic challenge (Wang et al., 2014b). Additionally, the related
metabolite glucosamine has been shown to extend murine lifespan
(Weimer et al., 2014). These studies point to the potential significance
of the hexosamine pathway in regulating protein quality control and
longevity. Previous work in this area also suggested that overactivation
of the hexosamine pathway could produce diabetic-like symptoms
(Hawkins et al., 1996). Thus, the activity and tissue responses of this
pathway will need to be optimized to achieve beneficial effects.
Interestingly, the long-lived naked mole rat harbors extensive hyaluro-
nan glycoconjugates (comprised of GlcNAC and glucuronic acid
subunits), thought to be protective against cancer and perhaps other
age-related diseases (Tian et al., 2013). Glycoconjugates are also
suggested to serve as predictive biomarkers of human aging (Dall’Olio
et al., 2013). Clearly, the hexosamine pathway could provide novel
targets to treat age-related disease and further work in this area is
merited.
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DNA damage signaling
Studies in mice provided the proof of principle that the deletion of
upstream DNA damage responses (Exo1-dependent end resection) and
downstream DNA damage checkpoints (p21-dependent cell cycle arrest,
Puma-dependent apoptosis) can prolong tissue maintenance and
increase the lifespan of aging telomerase-deficient mice (Choudhury
et al., 2007; Schaetzlein et al., 2007; Sperka et al., 2011; Wang et al.,
2012). This is a potential anti-aging target as telomere dysfunction and
DNA damage accumulate in aging human stem cells and tissues (Jiang
et al., 2008). Another connection between DNA damage signaling,
telomeres and aging discussed at the meeting was the noncanonical
activation of DNA damage pathways (e.g., ATM) by mitochondrial ROS
(Schroeder et al., 2013). This extends yeast chronological lifespan by
epigenetically silencing subtelomeric transcription, suggesting that
mitochondrial adaptive ROS signaling pathways could potentially be
targeted to extend healthspan.
Stem cells
During aging, adult tissue stem cells exhibit impairments in functionality
and exponential increases in premalignant mutations driven by cell-
intrinsic defects and alterations in the stem cell niche and the blood
circulatory environment (Ju et al., 2007; Behrens et al., 2014). Emerging
data indicate that the reversal of age-associated defects in stem cell
stability and function could help to improve tissue maintenance and to
prevent stem cell-derived carcinogenesis during aging (Patel & Demontis,
2014). Both stem cell-based interventions and other dietary and
pharmacological interventions which induce stem cell-based regenera-
tion and rejuvenation are likely to be very important for healthspan in the
future, but are currently only beginning to be tested as modulators of
lifespan in model organisms.
Retrotransposable elements
Evidence from multiple model systems, including yeast, Drosophila, and
more recently, mouse and human cell culture demonstrate that
retrotransposable elements become active during cellular senescence
and aging (De Cecco et al., 2013a,b; Sedivy et al., 2013). Active
retrotransposition is mutagenic and potentially highly destabilizing to
genomes. Given the importance of genome integrity as it relates to
cancer and aging, this raises the interesting and novel possibility that
activation of retrotransposition could contribute to some age-associated
pathologies. Some nucleoside reverse transcriptase inhibitors currently
used clinically to treat HIV infection, such as lamivudine or adefovir,
block retrotransposition of several endogenous elements, including
LINE1, the only known active retrotransposition family in human
genomes (Dai et al., 2011). While the current reverse transcriptase
inhibitors have adverse effects arguing against their long-term use in
humans as an anti-aging intervention, if studies in mice show beneficial
effects, new drugs could be developed specifically to target LINE1
elements.
Conclusions
Accumulating scientific evidence from studies conducted in various
organisms and species suggests that targeting aging will not just
postpone chronic diseases but also prevent multiple age-associated
metabolic alterations while extending healthy lifespan. A number of
pathways affecting metabolism, growth, inflammation, and epigenetic
modifications that alter the rate of aging and incidence of age-related
diseases have been identified. Interventions with the potential to
target these pathways safely and to induce protective and rejuvenat-
ing responses that increase human healthspan are becoming available.
These include intermittent or prolonged fasting, mild CR combined
with a low glycemic index diet and protein restriction, inhibition of
the GH/IGF-I axis, inhibition of TOR–S6K signaling, and activation
of sirtuins or AMPK. Additional pharmacological interventions such
as treatments with metformin, acarbose, spermidine, statins, and
b-blockers should also be evaluated. While not yet ready for
human trials, novel strategies including drugs that affect epigenetic
modifications or inhibit retrotransposition deserve additional research
and attention. Given the logistical issues of clinical studies aimed
primarily at prolonging lifespan or healthspan, the participants of the
workshop concluded that initial trials should be first designed to treat
age-related diseases and conditions (not specifically aging), and should
start with smaller cohorts, relatively short time periods, and a primary
focus on safety and tolerability. This approach is likely to provide
early clues for especially promising potential candidates that would
then merit lengthier or more detailed studies potentially focused on
aging.
In agreement with the title of this workshop Interventions to Slow
Aging in Humans: Are We Ready?, we, the members of this workshop,
believe that the time has come not only to consider several therapeutic
options for the treatment of age-related comorbidities, but to initiate
clinical trials with the ultimate goal of increasing the healthspan (and
perhaps longevity) of human populations, while respecting the guiding
principle of physicians primum non nocere.
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